📰 Markd Eisner News
Markd Eisner News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Markd Eisner. Real-time updates on events, politics, business and more.
May 29, 2024
Vir Biotechnology, Inc. announced that Mark D. Eisner, M.D., M.P.H. will join the company as Executive Vice President and Chief Medical Officer , effective June 03, 2024. Dr. Eisner will be a part of...
October 13, 2023
SOUTH SAN FRANCISCO, Calif. & SEATTLE--(BUSINESS WIRE)--Oct 13, 2023--
September 29, 2023
Sonoma Biotherapeutics, Inc., a clinical-stage biotechnology company developing engineered regulatory T cell (Treg) therapies for autoimmune and inflammatory diseases, today announced the appointments of Joseph R. Arron, M.D., Ph.D., as Chief...
July 21, 2023
FibroGen joins Illumina and Genentech in implementing job cuts among Bay Area biotech firms this year.
June 26, 2023
- Study did not meet the primary endpoint- Pamrevlumab was generally safe and well tolerated- ZEPHYRUS-2 Phase 3 study will be discontinued- Company to implement plan to extend cash runway into 2026 SAN FRANCISCO, June 26, 2023 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced topline results from its Phase 3 ZEPHYRUS-1 trial evaluating the safety and efficacy of pamrevlumab in patients with idiopathic pulmonary fibrosis (IPF). The study compared treatment with pamrevlumab to pla
June 26, 2023
A phase 3 study evaluating the efficacy and safety of pamrevlumab in patients with idiopathic pulmonary fibrosis did not meet its primary endpoint.
May 19, 2023
Roxadustat proved to be noninferior to recombinant erythropoietin alfa with regard to change in hemoglobin level from baseline to an average level during weeks 9 to 13 in patients receiving concurrent chemotherapy for non-myeloid malignancies in China, meeting the primary end point of an ongoing phase 3 trial.